Table 3.
Mutation frequencies as measured by next‐generation sequencing and Sanger sequencing technologies (where indicated*).
| Technology | Gene tested | No. tested | No. mutated | % |
|---|---|---|---|---|
| Mutation (NGS or # (NGS + Sanger) | ABL | 321 | 2 | 0.62 |
| AKT | 335 | 5 | 1.49 | |
| ALK | 337 | 0 | 0.00 | |
| APC | 335 | 12 | 3.58 | |
| ATM | 333 | 5 | 1.50 | |
| BRAF# (336 tested by NGS) | 442 | 1 | 0.23 | |
| BRCA1 | 87 | 5 | 5.75 | |
| BRCA2 | 87 | 8 | 9.20 | |
| CDH1 | 337 | 1 | 0.30 | |
| cKIT# (335 tested by NGS) | 388 | 4 | 1.03 | |
| cMET | 336 | 11 | 3.27 | |
| CSF1R | 336 | 1 | 0.30 | |
| CTNNB1 | 336 | 2 | 0.60 | |
| EGFR# (337 tested by NGS) | 360 | 3 | 0.83 | |
| ERBB4 | 334 | 3 | 0.90 | |
| FBXW7 | 335 | 14 | 4.18 | |
| FGFR1 | 337 | 0 | 0.00 | |
| FGFR2 | 337 | 0 | 0.00 | |
| FLT3 | 337 | 1 | 0.30 | |
| GNA11 | 294 | 0 | 0.00 | |
| GNAQ | 229 | 0 | 0.00 | |
| GNAS | 337 | 0 | 0.00 | |
| HER2 | 334 | 0 | 0.00 | |
| HNF1A | 307 | 3 | 0.98 | |
| HRAS | 299 | 8 | 2.68 | |
| IDH1 | 337 | 2 | 0.59 | |
| JAK2 | 337 | 0 | 0.00 | |
| JAK3 | 337 | 2 | 0.59 | |
| KDR | 335 | 3 | 0.90 | |
| KRAS# (333 tested by NGS) | 448 | 11 | 2.46 | |
| MLH1 | 334 | 0 | 0.00 | |
| MPL | 335 | 0 | 0.00 | |
| NOTCH1 | 333 | 0 | 0.00 | |
| NPM1 | 334 | 0 | 0.00 | |
| NRAS# (335 tested by NGS) | 381 | 4 | 1.05 | |
| PDGFRA | 333 | 4 | 1.20 | |
| PIK3CA# (328 tested by NGS) | 421 | 53 | 12.59 | |
| PTEN | 324 | 13 | 4.01 | |
| PTPN11 | 337 | 0 | 0.00 | |
| RB | 333 | 5 | 1.50 | |
| RET | 330 | 1 | 0.30 | |
| SMAD4 | 336 | 4 | 1.19 | |
| SMARCB1 | 336 | 0 | 0.00 | |
| SMO | 280 | 0 | 0.00 | |
| STK11 | 326 | 6 | 1.84 | |
| TP53 | 335 | 137 | 40.90 | |
| VHL | 303 | 0 | 0.00 |
Abbreviations: NGS, next‐generation sequencing; EGFR, epidermal growth factor receptor; PIK3CA, phosphatidylinositol 3‐kinase; PTEN, phosphatase and tensin homolog.